HER2-enriched breast cancers (ER−, PR−, HER2+, Ki-67high) are associated with an intermediate prognosis, especially due to the use of HER2-targeting antibodies blocking pro-oncogenic signaling [19]. The gene discussed is ERBB2; the disease is breast cancer.